Compare Abeona Therapeutics Inc (ABEO) vs TORM plc (TRMD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs TORM plc — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while TORM plc trades at $28.92 (market cap $2.87B). The key difference: TORM plc is far larger — about 7.7× Abeona Therapeutics Inc's market cap, and TORM plc pays a 9.87% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | TRMD | |
|---|---|---|
Market Cap | $373.32M | $2.87B |
Sector | Health | Technology |
52-Week High | $7.23 | $34.87 |
52-Week Low | $4.17 | $17.33 |
Enterprise Value | $228.22M | $3.76B |
Dividend Yield | — | 9.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
TRMD trades at $27.99, up 1.05% today, with neutral technical signals and strong fundamentals. The stock shows attractive valuation metrics with P/E of 8.21 and P/B of 1.26, supported by robust profitability including 24.41% net margin and 15.62% ROE. Recent earnings showed mixed results with Q4 2025 beat but Q1 2026 miss, while Q2 2026 expectations are set at $3.3 EPS. The company maintains strong cash generation with $498.9M operating cash flow in 2025 and recently declared a $0.70 dividend.
Outlook remains positive with 100% analyst buy ratings and improving 2026 revenue guidance to $1.4B. Key opportunities include undervaluation relative to peers and strong dividend yield near 9%. Risks include earnings volatility from tanker market fluctuations and negative net cash flow trends. The stock presents value for income-focused investors despite cyclical industry exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
